

University of Rhode Island

DigitalCommons@URI

---

Institute for Immunology and Informatics  
Faculty Publications

Institute for Immunology and Informatics  
(iCubed)

---

10-22-2009

## P19-43. Regulatory T Cell Epitopes in a Dendritic Cell-Targeted HIV Vaccine Delivery Platform

C. Weber

C. Weber

Leonard Moise

*University of Rhode Island, lmoise@uri.edu*

H. Veelken

W. Martin

Follow this and additional works at: [https://digitalcommons.uri.edu/immunology\\_facpubs](https://digitalcommons.uri.edu/immunology_facpubs)

---

### Citation/Publisher Attribution

C Weber, C Weber, L Mosie, H Veelken and W Martin. (2009). "P19-43. Regulatory T cell epitopes in a dendritic cell-targeted HIV vaccine delivery platform." *Retrovirology*, 6(Suppl 3), P363. Available at: <http://www.retrovirology.com/content/6/S3/P363>

This Article is brought to you by the University of Rhode Island. It has been accepted for inclusion in Institute for Immunology and Informatics Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact [digitalcommons-group@uri.edu](mailto:digitalcommons-group@uri.edu). For permission to reuse copyrighted content, contact the author directly.

---

## **P19-43. Regulatory T Cell Epitopes in a Dendritic Cell-Targeted HIV Vaccine Delivery Platform**

### **Publisher Statement**

© 2009 Weber et al; licensee BioMed Central Ltd.

### **Terms of Use**

All rights reserved under copyright.

Poster presentation

Open Access

## PI9-43. Regulatory T cell epitopes in a dendritic cell-targeted HIV vaccine delivery platform

C Weber<sup>1</sup>, C Weber\*<sup>1</sup>, L Mosie<sup>2</sup>, H Veelken<sup>1</sup> and W Martin<sup>2</sup>

Address: <sup>1</sup>University of Freiburg, Freiburg, Germany and <sup>2</sup>EpiVax, University of Rhode Island, Providence, RI, USA

\* Corresponding author

from AIDS Vaccine 2009  
Paris, France. 19–22 October 2009

Published: 22 October 2009

*Retrovirology* 2009, **6**(Suppl 3):P363 doi:10.1186/1742-4690-6-S3-P363

This abstract is available from: <http://www.retrovirology.com/content/6/S3/P363>

© 2009 Weber et al; licensee BioMed Central Ltd.

### Background

Dendritic cell-targeting antibodies (e.g. anti-DEC-205) are used to deliver HIV vaccine immunogens for antigen presentation. As antibodies contain sequences that contribute to immunosuppression induced via regulatory T cells, we are modifying the anti-DEC-205 sequence to reduce its tolerogenicity to make it an effective HIV vaccine delivery vehicle.

### Methods

IgG sequences were computationally screened for T-cell epitopes using EpiMatrix. Class II HLA competition binding assays were performed to validate predicted epitope peptides. T cell functional and immunophenotyping assays were performed using peptide-stimulated PBMCs provided by healthy human donors.

### Results

Six highly promiscuous HLA class II T-cell epitopes in both the heavy and light chain constant domains of IgG were identified computationally. Epitopes were synthesized and shown to bind multiple HLA class II molecules with high affinity. These sequences specifically upregulate FoxP3 expression of CD4<sup>+</sup>CD25<sup>high</sup> T cells from healthy human donors. Co-incubation of these epitopes with various self and foreign antigens leads to antigen-specific suppression of effector T cell proliferation and cytokine secretion and an increase in IL-10 and CTLA-4 expression suggesting conversion of Teff to adaptive Tregs. The anti-DEC-205 sequence was computationally screened for putative HLA DR4-restricted, regulatory T-cell epitopes using EpiMatrix. Epitopes were analyzed using OptiMatrix

to select mutations that will reduce epitope binding affinity for HLA. Five regulatory T-cell epitopes were computationally identified. Per epitope, three modified sequences were selected and synthesized.

### Conclusion

These studies suggest that Treg epitopes in IgG may be responsible for antigen-specific tolerance observed for vaccine antigens targeted to dendritic cells via anti-DEC-205. Modification of regulatory T-cell epitopes may significantly diminish tolerogenicity, enabling the use of modified anti-DEC-205 as a HIV antigen-delivery system that obviates the dangers associated with non-specific activation of the immune system.